@neverboringever's peptide warning, fact-checked

What did @neverboringever actually say?

The creator says her friend, a 34-year-old competitive athlete and firefighter, nearly died from anaphylactic shock minutes after injecting a peptide called "Sir Morlin" or "Simarillin." She describes a cascade of severe symptoms: seizures, loss of bladder and bowel control, vomiting, extreme vision loss, and cardiac arrest at the hospital. The friend had used injectable peptides for about a year and had experienced minor prior reactions, including "light hives" and flushing. The creator frames this as a warning for anyone already using or considering injectable peptides, and points to online forums where she found "dozens of entries" of similar reactions. The core message is straightforward: a serious, near-fatal allergic reaction can happen even after months of apparently tolerating these substances.

Does the science back this up?

Yes, in general terms. Anaphylaxis from injectable compounds is real and documented, and the prior history of mild injection-site reactions the friend experienced is clinically significant as a warning sign. However, the specific compound name here is a problem.

The peptide she calls "Sir Morlin" or "Simarillin" does not match any established peptide in the research or pharmaceutical literature by that phonetic description. It may be a garbled reference to Sermorelin, a growth hormone-releasing hormone analogue used off-label by some athletes. If that is what was used, Sermorelin is not FDA-approved for general use in healthy adults, and it is typically sourced from compounding pharmacies, which are not subject to the same manufacturing controls as FDA-approved drugs. A 2023 FDA warning explicitly flagged contamination and sterility risks in compounded peptide products. Allergic responses to improperly manufactured injectables are well documented. A case series by Castells et al. (2021, Journal of Allergy and Clinical Immunology) confirmed that injectable biologics and peptide-adjacent compounds carry genuine anaphylaxis risk, particularly when impurities are present.

What did they get wrong (or right)?

The creator gets the core biology right: anaphylaxis from injectable peptides is a documented, if underreported, risk. She also correctly notes that prior mild reactions, those "light hives" and flushing episodes, can precede more severe events. That progression is consistent with sensitization patterns described in allergy literature.

What she gets wrong, or at least muddies, is the compound identification. "Simarillin" is not a recognized peptide name. If the friend was using Sermorelin sourced from an unregulated or compounding source, that context matters enormously. Compounded peptides are not equivalent to pharmaceutical-grade products, and the risk calculus changes when you cannot verify sterility, concentration, or even what is actually in the vial. The creator treats this as a warning about peptides as a category, which is partially fair, but she skips the part about where these compounds are coming from and what that means for safety.

She also cites forum posts as evidence of widespread similar reactions. Forum posts are not clinical data. They are worth noting, but they are not the same as a pharmacovigilance database or a controlled case series.

What should you actually know?

If you are injecting any peptide sourced outside a licensed, regulated pharmacy, you are taking on risks that go well beyond the peptide itself. Compounding facilities vary dramatically in quality control. The FDA has issued multiple warnings about contaminated peptide vials, including instances of bacterial contamination and inaccurate dosing. A person who has had any prior injection-site reaction, hives, flushing, or nausea, has shown a pattern that a physician would treat as a red flag requiring evaluation before continuing.

Anaphylaxis is not predictable from prior tolerance. The immune system can mount an escalating response over repeated exposures, which is exactly what appears to have happened here. If you experience any systemic reaction after an injection (not just local redness, but hives spreading beyond the site, difficulty breathing, dizziness, or GI symptoms), that is a reason to stop and seek medical evaluation immediately, not to continue and monitor. Carrying an epinephrine auto-injector is standard practice for anyone with a documented history of allergic reactions, and a physician supervising peptide use should be aware of that history.